Ispaghula husk

Generic Medicine Info
Indications and Dosage
Adult: 3.5 g 1-3 times daily. Mix w/ a full glass of liq.
Child: ≤12 yr Each level 5-mL spoonful contains 1.75 g: Half to 1 level 5-mL spoonful bid (morning and evening) to be dissolved in water.

Mild to moderate hypercholesterolaemia
Adult: As adjunct to lipid-lowering diet: 7.5-10 g daily. Mix w/ a full glass of liq.
Should be taken on an empty stomach. Take before meals w/ a full glass of water.
Pre-existing faecal impaction, intestinal obstruction, natural or drug-induced reduction of gut motility, colonic atony e.g. senile megacolon.
Special Precautions
Patient w/ swallowing difficulty. Childn.
Adverse Reactions
Abdominal distention, flatulence, GI impaction, GI obstruction, hypersensitivity reactions e.g. rhinitis, conjunctivitis, bronchospasm and anaphylaxia; cutaneous symptoms (e.g. exanthema and/or pruritus).
Symptoms: Abdominal discomfort and flatulence. Management: Maintain adequate fluid intake.
Drug Interactions
May delay or reduce the GI absorption of other drugs e.g. cardiac glycosides, coumarin derivatives, lithium, or vit (e.g. vit B12) and minerals (e.g. Ca, Fe, or Zn).
Mechanism of Action: Ispaghula husk absorbs water in the GI tract to form a mucilaginous mass which increases faecal mass, thereby promoting peristalsis.
Store below 30°C.
MIMS Class
Laxatives, Purgatives
ATC Classification
A06AC01 - ispaghula (psylla seeds) ; Belongs to the class of bulk-producing laxatives.
Buckingham R (ed). Ispaghula. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 11/04/2016 .

Guardian - Psyllium Husk Powder for Suspension (Guardian). DailyMed. Source: U.S. National Library of Medicine. Accessed 11/04/2016 .

Joint Formulary Committee. Ispaghula Husk. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 11/04/2016 .

Disclaimer: This information is independently developed by MIMS based on Ispaghula husk from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in